TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Wave Life Sciences
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences reported significant Activin E reductions of up to 85% in its INLIGHT clinical trial for obesity treatment, with WVE-007 showing promising results in fat loss potential and safety profile across multiple dose cohorts.

Insights
JPMpJ   neutral

Maintains a steady portfolio position at 4.0% of assets


WVE   positive

Demonstrated dose-dependent Activin E reductions, positive safety profile, successful clinical trial progression, and promising potential for obesity treatment with WVE-007